echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Zuranolone Phase III Clinical Success for Major Depression

    Zuranolone Phase III Clinical Success for Major Depression

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    news

    news

    Sage and Biogen announced today that their GABA receptor modulator Zuranolone achieved primary endpoints in a Phase 3 clinical trial called CORAL


    Drug source analysis

    Drug source analysis

    Zuranolone is a neurosteroidal GABA-A receptor allosteric modulator that can simultaneously modulate synaptic and outer synaptic GABA receptors by binding to different binding sites of traditional GABA receptor ligands such as BZD and Z-drugs , and therefore may have anticonvulsant, antidepressant, and therapeutic activity in senile degenerative diseases such as AD in addition to hypnosis


    Major depression is a serious unmet medical need, and a major advantage of Zuranolone is its rapid onset of action


    HAMD-17 consists of 17 indicators, including three categories of insomnia and two categories of anxiety


    Consistent with the mechanism of GABA agonists, the main side effects of this product are drowsiness and dizziness, which are said to be nothing compared to the side effects of existing antidepressants


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.